DuPont de Nemours, Inc. DD
Composite 43/100; the shares have moved about 30% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 10/100 — a strong mark against it.
Balance-sheet strength ranks 59/100 — a slight point in its favour. Income ranks 56/100 — a slight point in its favour. Momentum ranks 53/100 — a slight point in its favour.
Growth ranks 10/100 — a strong mark against it. Quality ranks 36/100 — a moderate mark against it.
What the company does DuPont de Nemours, Inc. (DD) supplies specialty chemicals and engineered materials across healthcare, water, and industrial markets. Its segments include Healthcare & Water Technologies (medical devices, filtration) and Diversified Industrials (construction, automotive, aerospace components).
Key financials Profitability is weak: ROE 2%, ROA 2%, ROCE 4%, net margin 1%. Revenue fell 45% and EPS 87% year-over-year. Gross margin 35% supports operations, but high interest costs (coverage 3.22) and leverage (Debt/Equity 0.23) constrain flexibility.
Stock health Sideravia scores Quality 36/100 (Poor) and Growth 10/100 (Weak), offset by Strength 56/100 and Valuation 49/100 (fair). Piotroski F-Score 6/9 and Altman Z 0.63 indicate moderate financial stress. RSI(14) 41 suggests neutral momentum.
Price vs fair value The stock trades at a **discount of 25%** versus the analyst mean target of 170.00. - Net margin 1% (below sector norms) - Forward P/E 19.57 vs trailing 61.42 (multiple compression) - Revenue growth -44% and EPS growth -87% (sharp declines) - Valuation percentile 49/100 (near median)
Looking forward Forward PEG 0.09 implies potential value if growth rebounds, but current margins and leverage limit upside. Momentum remains fragile with 12-month return 43% but recent 3-month decline 8%. Income yield 2% and payout ratio 29% support modest yield appeal.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.